Evidence map›Paper›PMID 41217951›Full record

SynthesisCancer control : journal of the Moffitt Cancer Center

Neoadjuvant vs. Adjuvant Chemotherapy for Luminal B Breast Cancer: A Systematic Review and Meta-Analysis - Where is the Evidence?

Luke Bromley, Christopher Harris, Luke Ardolino, Guy Eslick, Sanjay Warrier, Adam Ofri

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luke BromleyDepartment of Surgery, Austin Health, Melbourne, Victoria, Australia.ORCID 0000-0002-8437-7299
Christopher HarrisFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Luke ArdolinoFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Guy EslickFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Sanjay WarrierFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Adam OfriFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionChemotherapy is used frequently in the neoadjuvant setting for breast cancers, most commonly triple negative and human epidermal growth factor receptor 2 (HER-2) positive breast cancer. Certain hormone positive HER-2 negative cancers known as luminal B have shown response to adjuvant chemotherapy and can be considered in the neoadjuvant setting. This meta-analysis reviews survival outcomes in neoadjuvant chemotherapy in comparison to adjuvant in luminal B breast cancer.MethodsPubMed, Medline, and Embase were accessed on the 31

Indexed as

Breast NeoplasmsNeoadjuvant TherapyChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesFemaleHumansErb-b2 Receptor Tyrosine Kinasesbreast cancerhormone positive HER2 negativeluminal bneoadjuvant chemotherapyoverall survival

Identifiers

PMID41217951
PMCPMC12605877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.